The FOXL2 mutation was absent in 149 additional epithelial ovarian tumors and in 180 breast cancers . Sample GCT18, a thecoma, was the only real non-GCT tumor that was positive for the FOXL2 variant in the first validation series. Further evaluation of the sample revealed a granulosa-cell component . 7 in the Supplementary Appendix). By sequencing cloned PCR products, we observed these variants had been in cis. We completed fluorescence in situ hybridization to assess potential amplification of FOXL2 on 32 GCTs and 5 epithelial ovarian cancers and obtained negative outcomes . Test for Replication We obtained another group of 95 clinical samples to determine the specificity of this variant within SCSTs of the ovary .The parameters assessed were the following: left ventricular internal diameter at end-diastole/end-systole , remaining ventricular anterior wall at end-diastole/end-systole , left ventricular volume at end-diastole/end-systole , still left ventricular mass , still left ventricular posterior wall structure at end-diastole/end-systole , remaining ventricle ejection fraction , left ventricle fractional shortening and left ventricular fractional area change . The dosage of sirtinol found in the experiments was 1. SIRT1 inhibitors were first dissolved in stock solutions of DMSO, and for treatment, the ultimate focus of DMSO was 0.2 percent .